<SEC-DOCUMENT>0001144204-18-049318.txt : 20180913
<SEC-HEADER>0001144204-18-049318.hdr.sgml : 20180913
<ACCEPTANCE-DATETIME>20180913152820
ACCESSION NUMBER:		0001144204-18-049318
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180913
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180913
DATE AS OF CHANGE:		20180913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		181068810

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv502849_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 185.85pt 0pt 200.95pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 63.9pt 0pt 78.85pt; text-align: center"><B>SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 188.75pt 0pt 200.8pt; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 214.8pt 0pt 227pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Pursuant to Section 13 or 15(d) of the Securities&nbsp;Exchange
Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Date of report (Date of earliest event reported): September 13, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 151.3pt 0pt 163pt; text-align: center"><FONT STYLE="font-size: 16pt"><B>STAAR
Surgical Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 151.3pt 0pt 163pt; text-align: center"><B>(Exact Name of Registrant
as Specified in Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Delaware</U></FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><U>0-11634</U></TD>
    <TD STYLE="width: 33%; text-align: center"><U>95-3797439</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center"><B>(State or Other Jurisdiction</b></TD>
    <TD STYLE="text-align: center"><B>(Commission</B></TD>
    <TD STYLE="text-align: center"><B>(I.R.S. Employer</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center"><B>of Incorporation)</B></TD>
    <TD STYLE="text-align: center"><B>File Number)</B></TD>
    <TD STYLE="text-align: center"><B>Identification No.)</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-align: center"><U>1911 Walker Ave., Monrovia, California</U></TD>
    <TD STYLE="text-align: center"><U>91016</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-align: center"><B>(Address of Principal Executive Offices)&#9;</B></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Registrant&rsquo;s Telephone Number, Including Area
Code <U>626-303-7902&#9;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Not Applicable</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<B>(Former Name or Former Address, if Changed Since Last
Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (<I>see</I> General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR
 &sect;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.2pt 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">Emerging
growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
                            7.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
FD Disclosure.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 13, 2018, STAAR Surgical Company
issued a press release announcing receipt of a letter from the U.S. Food and Drug Administration approving the PMA Supplement for
the Visian Toric ICL for the correction of myopia with astigmatism. A copy of the press release is furnished as Exhibit 99.1 to
this Report and is incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information furnished herewith pursuant
to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be &ldquo;filed&rdquo; for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities
of that section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any filing under
the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless
of any general incorporation language in the filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
                            9.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Statements and Exhibits</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
                            No.</U></B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Description</U></B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 1in"><A HREF="tv502849_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD><TD STYLE="text-align: justify"><A HREF="tv502849_ex99-1.htm" STYLE="-sec-extract: exhibit">Press
Release dated September 13, 2018.</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">STAAR Surgical Company&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 13, 2018</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 82%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Caren Mason</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Caren Mason</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.6pt 0pt 5pt">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.6pt 0pt 5pt"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv502849_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><B></B></P>

<P STYLE="font: 10pt Courier; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 50.25pt; width: 249pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 81pt 0pt 1in; text-align: center"><B>STAAR Surgical Announces Approval
by the FDA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 81pt 0pt 1in; text-align: center"><B>of the Visian Toric ICL for the Correction of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 81pt 0pt 1in; text-align: center"><B>Myopia with Astigmatism</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>MONROVIA, CA, September 13, 2018</B>---STAAR Surgical Company
(NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye,
is today announcing that the FDA has granted approval of the PMA Supplement for the Visian Toric ICL for the correction of myopia
with astigmatism.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This approval represents a meaningful expansion of the Implantable
Collamer&reg; Lens (ICL) product line for the correction of refractive error in patients with both myopia and astigmatism which
are common conditions in the United States (US). Astigmatism affects approximately 30 percent of the population. <SUP>1</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ICL in both spherical and toric designs has been associated
with significant improvements in quality of life. Patients have described ICL surgery as &ldquo;life changing&rdquo; or wished
they had opted for the surgery sooner <SUP>2</SUP>. The approval of the Visian Toric ICL is also an important step towards the
future availability of advanced ICL models in the US, such as the EVO/EVO<SUP>+</SUP> Toric ICL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;FDA&rsquo;s approval of STAAR&rsquo;s Visian Toric ICL
in the US provides an exciting treatment option for myopic patients with astigmatism in search of visual freedom. We are thrilled
to be able to offer this lens in the United States and look forward to officially making the Visian Toric ICL available to U.S.
Surgeons for their patients on November 1<SUP>st</SUP>, 2018&rdquo;, said Caren Mason, President &amp; CEO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt; text-align: right">1</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INDICATIONS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Directions for Use (DFU) lists the indications as: The Visian
TICL is indicated for use in patients 21&ndash; 45 years of age:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1. for the correction of myopic astigmatism with spherical
equivalent ranging from -3.0 D to &le; -15.0 D (in the spectacle plane) with cylinder (spectacle plane) of 1.0 D to 4.0 D in the
spectacle plane.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">2. for the reduction of myopic astigmatism with spherical
equivalent ranging from greater than -15.0 D to -20.0 D (in the spectacle plane) with cylinder (spectacle plane) 1.0 D to 4.0 D
in the spectacle plane.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">3. with an anterior chamber depth (ACD) of 3.00 mm
or greater, when measured from the corneal endothelium to the anterior surface of the crystalline lens and a stable refractive
history (within 0.5 D for both spherical equivalent and cylinder for 1 year prior to implantation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">4. The Visian TICL is intended for placement in the
posterior chamber (ciliary sulcus) of the phakic eye.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><SUP>1</SUP> 2017 Refractive Surgery
Report: A Global Analysis from 2016 &ndash; 2022, <I>Market Scope December 2017</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><SUP>2</SUP> Ieong A.et al, Quality
of Life in High Myopia before and after Implantable Collamer Lens Implantation. <I>Ophthalmology 2010;117:2295-2300</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About STAAR Surgical</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STAAR, which has been dedicated solely to ophthalmic surgery
for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems.
These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact
lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR&rsquo;s lens
used in refractive surgery is called an Implantable Collamer&reg; Lens or &ldquo;ICL&rdquo;, which includes the EVO Visian ICL&trade;
product line. More than 900,000 Visian ICLs have been implanted to date. To learn more about the ICL go to: <U>www.discovericl.com.
</U>STAAR has approximately 400 full-time equivalent employees and markets lenses in over 75 countries. Headquartered in Monrovia,
CA, the company operates manufacturing facilities in Aliso Viejo, CA and Monrovia, CA. For more information, please visit the
Company&rsquo;s website at <U>www.staar.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt; text-align: right">2</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Forward-Looking Statements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This news release contains forward-looking statements.&nbsp;
These statements include but are not limited to statements regarding the commercial significance of the Visian Toric ICL in the
US market.&nbsp; Forward-looking statements are based on our management&rsquo;s current expectations or beliefs regarding future
events or circumstances, and you should not place undue reliance on these statements.&nbsp; Such statements involve known and unknown
risks, uncertainties, assumptions and other factors, many of which are out of STAAR&rsquo;s control and difficult to forecast that
may cause actual results to differ materially from those that may be described or implied in the forward-looking statements.&nbsp;
STAAR cannot be certain about the commercial success of the Visian Toric ICL in the US market.&nbsp; For a discussion of certain
other risks, uncertainties and other factors affecting the statements contained in this news release, see STAAR&rsquo;s Annual
Report on Form 10-K for the year ended December 29, 2017, under the caption &ldquo;Risk Factors,&rdquo; which is on file with the
SEC and available in the &ldquo;Investor Information&rdquo; section of STAAR&rsquo;s website under the heading &ldquo;SEC Filings&rdquo;.&nbsp;
Except as required by law, STAAR assumes no, and hereby disclaims any, obligation to update any of the foregoing or any other forward-looking
statements.&nbsp; STAAR nonetheless reserves the right to make such updates from time to time by press release, periodic report
or other method of public disclosure without the need for specific reference to this news release.&nbsp; No such update shall be
deemed to indicate that other statements not addressed by such update remain correct or create an obligation to provide any other
updates.</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left">CONTACT:</TD><TD STYLE="text-align: justify"><B>Investors &amp; Media</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 1in; text-indent: 0in; text-align: justify">EVC
Group</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 1in; text-indent: 0in; text-align: justify">Brian
Moore, 310-579-6199</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 1in; text-indent: 0in; text-align: justify">Doug
Sherk, 415-652-9100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt; text-align: right">3</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 40&3 P$1  (1 0,1 ?_$ +4  0 !! ,  P
M       ) 0<("@(%!@,$"P$!  ,  P$!              $" P0&!P4($
M!@(" 0,"! $'!@\    ! @,$!08 !Q$("2$2$S$402(5"E%A<9&Q,B06\(%"
M([87H<%B5"5UM38G=QB(.7DZ$0 " 0(% @,& @@%!0       0(1 R$Q$@0%
M009180?P<8$B,A.AP9&Q0E)B<B,4T>&"%0@S0R0T%O_:  P# 0 "$0,1 #\
MW]LXY(P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , <A],E)O(FA03 'H(\
M8HR  @/T'(H155IU*X)& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!Q$Y2B "/'(\!_0(_U!
MDJ+:;Z)$55:/!]//W>)Y6V7RE4.*5G;O;*]4(9$#">3LLNQA67)0$PE(O(KM
MR*J<%'@I>3#^ 9K9V]_<-*S"4F_!,X>_Y+CN*LN_R5^S8M)5;N3C'!>]HP>N
MOE$Z;U)91LVV+(W%RD(E.6E56;F$ ,4WM,!7[IO&QRH<_02+&*(#R B&=CVG
M9O<.[@IPV\E:?5M+\Z_@>5\AZZ^FFSONQ:WKW=V.?V+=R[%/]URBM*?Q+1J^
M8GK""QB)U[;QD@-P58*K!@42\_V_8I9"JA_,)><^DO3WGTJ1<4O.K_(^!<_Y
M&=A6YZ;L-]&7@K=M8>-+DHR_"G@7$J/E9Z>V-P1M(6ZTTX3<!\]LI<NW:\C^
M)W4*$V@B4/Q$WM#.+N.Q>XK$=;M*<?%2C5_"J?X'V>+]>O3GDIPM?W<[-R72
MY;DFL?VI13A^AM&;NO\ <&K=K1P2FMK_ %2[LP(4Z@UR:923EL!OH#QB@J+]
MD?\ Y*R9#!^(9UC=;+>;)Z=S:G%^:9ZCQ//<+SMK[W#;JQN;2;3=N<94:S3H
MZI^3+BE4*< $H_V@Y#T^H<\9QDFZTZ'U=2IC@WT>#_1F<\@D8!03 'IZC_,
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M] X'53<%]J9Q Q3 (\:8KZLC*3M91J;(1?4I?Y0#^K(2JZ&3/SP?(EYD._\
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MQ@R=G>G.[IS06X+!56R3*LW=W%"Y"'N,>Q;%391[J3!@Y3<HH%31$Z!52)I
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M;+GX(DJ8##Z!QD_%>WP*/3TJ3/Y5^61 P!@# & , 8!\9DBF'D>>?;[>>?\
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M50 <8(2H,$E.,5(<4RN"5@4XR:D:45R"1@# :J4 .,$)4*B'. U4 '&"4J#
M& , 8 P!@ 0YP0U4IP'\O].34C2O,J <9!9*@P!@# & , 8 P!@%!#G!#297
M!*5,!@# & , ?7 :J #C!"5!@D8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
E@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
